Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0606920210290050455
Biomolecules & Therapeutics
2021 Volume.29 No. 5 p.455 ~ p.464
Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders
Han Yong-Hyun

Lee Kyeong-Jin
Saha Abhirup
Han Ju-Hyeong
Choi Hae-Na
Noh Min-Soo
Lee Yun-Hee
Lee Mi-Ock
Abstract
Uncontrolled inflammation is considered the pathophysiological basis of many prevalent metabolic disorders, such as nonalcoholic fatty liver disease, diabetes, obesity, and neurodegenerative diseases. The inflammatory response is a self-limiting process that produces a superfamily of chemical mediators, called specialized proresolving mediators (SPMs). SPMs include the ¥ø-3-derived family of molecules, such as resolvins, protectins, and maresins, as well as arachidonic acid-derived (¥ø-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, and alleviation of pain and promote tissue regeneration via novel mechanisms. SPMs function by binding and activating G protein-coupled receptors, such as FPR2/ALX, GPR32, and ERV1, and nuclear orphan receptors, such as ROR¥á. Recently, several studies reported that SPMs have the potential to attenuate lipid metabolism disorders. However, the understanding of pharmacological aspects of SPMs, including tissue-specific biosynthesis, and specific SPM receptors and signaling pathways, is currently limited. Here, we summarize recent advances in the role of SPMs in resolution of inflammatory diseases with metabolic disorders, such as nonalcoholic fatty liver disease and obesity, obtained from preclinical animal studies. In addition, the known SPM receptors and their intracellular signaling are reviewed as targets of resolution of inflammation, and the currently available information on the therapeutic effects of major SPMs for metabolic disorders is summarized.
KEYWORD
Specialized pro-resolving mediators, Resolvins, Maresins, NAFLDs, Adipose tissue
FullTexts / Linksout information
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed